Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yangxue Qingnao Granules for Post-Thrombolytic Hemorrhage Transformation
NCT06344312Active, not recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of Yangxueqingnao in ischemic stroke (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Proportion of subjects with Modified Rankin Scale score <= 1 at 90 days. Started Jan 2024; status: active, not recruiting.
02
Drugs
Yangxueqingnao
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06344312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06344312.